DSM is partnering with Amyris to fund the development of the technology to produce Vitamin A on a cost-advantaged basis. Once scaled, DSM will take the product to market utilizing its global channel and market access for animal and human nutrition and health. Amyris will develop, scale and produce a key ingredient for Vitamin A to supply exclusively to DSM.
“We are pleased to announce our second major product development and production agreement with DSM that we expect will end up being one of several going forward. This agreement is consistent with our collaboration business model and includes payment for development and value share on product production and delivery,” said John Melo, President & CEO of Amyris.